The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

The Journal of Immunology, 2008, 180, 1854-1865
Copyright © 2008 by The American Association of Immunologists, Inc.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ramirez, S. H.
Right arrow Articles by Persidsky, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ramirez, S. H.
Right arrow Articles by Persidsky, Y.

Activation of Peroxisome Proliferator-Activated Receptor {gamma} (PPAR{gamma}) Suppresses Rho GTPases in Human Brain Microvascular Endothelial Cells and Inhibits Adhesion and Transendothelial Migration of HIV-1 Infected Monocytes1

Servio H. Ramirez*,{dagger}, David Heilman*,{dagger}, Brenda Morsey*,{dagger}, Raghava Potula*,{dagger}, James Haorah*,{dagger} and Yuri Persidsky2,*,{dagger},{ddagger}

* Center for Neurovirology and Neurodegenerative Disorders, {dagger} Department of Pharmacology/Experimental Neuroscience, and {ddagger} Department of Pathology/Microbiology, University of Nebraska Medical Center, Omaha, NE 68198


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Under inflammatory conditions (including HIV-1 encephalitis and multiple sclerosis), activated brain endothelium enhances the adhesion and transmigration of monocytes across the blood-brain barrier (BBB). Synthetic ligands that activate the peroxisome proliferator-activated receptors (PPARs) have anti-inflammatory properties, and PPAR stimulation prevents the interaction of leukocytes with cytokine stimulated-endothelium. However, the mechanism underlying these effects of PPAR ligands and their ability to intervene with leukocyte adhesion and migration across brain endothelial cells has yet to be explored. For the first time, using primary human brain endothelial cells (BMVEC), we demonstrated that monocyte adhesion and transendothelial migration across inflamed endothelium were markedly reduced by PPAR{gamma} activation. In contrast to non-brain-derived endothelial cells, PPAR{alpha} activation in the BMVEC had no significant effect on monocyte-endothelial interaction. Previously, our work indicated a critical role of Rho GTPases (like RhoA) in BMVEC to control migration of HIV-1 infected monocytes across BBB. In this study, we show that in the BMVEC PPAR{gamma} stimulation prevented activation of two GTPases, Rac1 and RhoA, which correlated with decreased monocyte adhesion to and migration across brain endothelium. Relevant to HIV-1 neuropathogenesis, enhanced adhesion and migration of HIV-1 infected monocytes across the BBB were significantly reduced when BMVEC were treated with PPAR{gamma} agonist. These findings indicate that Rac1 and RhoA inhibition by PPAR{gamma} agonists could be a new approach for treatment of neuroinflammation by preventing monocyte migration across the BBB.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Adhesion of monocytes to activated brain endothelium plays an important role in the transmigration across the blood brain barrier (BBB)3 during inflammation of the CNS (1). Under physiological conditions, immune surveillance by lymphocytes crossing BBB is minimal and monocyte infiltration is practically undetectable; however, during the development of autoimmune disorders (i.e., multiple sclerosis) or virus driven diseases (i.e., HIV-1 encephalitis), leukocyte migration through the BBB increases considerably (2, 3, 4, 5). Enhanced leukocyte transendothelial migration is attributed to the activation of both the brain microvascular endothelial cells (BMVEC) and immune cells by proinflammatory cytokines. Cytokine activation promotes up-regulation of integrins in leukocytes and adhesion molecules (e.g., ICAM-1, and VCAM-1) on the BMVEC, which strengthen leukocyte-endothelial interactions leading to increase in transendothelial migration (6, 7). Thus, prevention of the initial leukocyte-endothelial interaction or reduction of the BMVEC controlled leukocyte passage could provide novel therapeutic avenues to lessen neuroinflammation.

Peroxisome proliferator-activated receptors (PPARs) are transcriptional regulators and members of a nuclear receptor family that include the closely related PPAR{alpha}, PPARβ/{delta}, and PPAR{gamma}, (8). PPARs play important roles in regulation of adipocyte differentiation, insulin sensitivity, anti-inflammatory responses, and antiproliferative effects in certain tumors (9). In recent years, the lipid lowering fibrates, which activate PPAR{alpha} and the insulin sensitizing thiazolidinediones (TZDs), which activate PPAR{gamma} have proven useful as potent anti-inflammatory agents (10). Ligand binding of PPAR promotes the heterodimerization with the retinoid x receptor inducing PPAR transactivation of target genes. In addition, activation of PPARs can also lead to transrepression, a process that has been shown to negatively interfere with key transcription factors (e.g., NF-{kappa}B, AP-1, STAT1, and sp1) involved in inflammatory responses. Stimulation of PPARs down-regulated the expression of proinflammatory genes such as IL-1β, IL-6, inducible NO synthase, cyclooxygenase-2, and various chemokines (11). Additionally, PPARs were found to decrease endothelial-leukocyte interactions in models of atherosclerosis (12, 13). Although these inhibitory effects on monocyte adhesion by PPAR activation have been in part attributed to suppression of adhesion molecules in the endothelial cells, the precise mechanism remains elusive. Recently, the effects of PPAR on the Rho pathway was identified in smooth muscle cells (14) in which PPAR{gamma} stimulation via the phosphatase SHP-2 inactivated RhoA/Rho kinase signaling. These results could provide an intriguing possibility for the modulation of GTPases by PPAR isotypes, because GTPases are important mediators of leukocyte-endothelial interaction.

Although much is known about key pathways involved in leukocyte extravasation, signaling events in the BMVEC actively participating in this process remain unclear (15). Small GTP-binding proteins such as RhoA and Rac1 regulate in transendothelial leukocyte migration (reviewed in Ref. 16). Rac1 was shown to mediate the clustering of adhesion molecules on the surface of endothelial cells essential for leukocyte docking. Consequently, firm adhesion of leukocytes to the endothelium signals to RhoA in endothelial cells leading to cytoskeletal rearrangement required for junctional modification and leukocyte paracellular transmigration. In inflammation, cytokine stimulation activates of the Rho family of GTPases, but it does not result in junctional disassembly unless an additional stimulus is provided like coculture with monocytes or Ab cross-linking of ICAM-1 and VCAM-1 (simulating leukocyte docking) (17, 18, 19). Therefore, the Rho family of GTPases provides a key molecular switch routing intracellular signaling events needed for transendothelial migration.

One area where PPAR anti-inflammatory effects have remained largely unexplored is in the context of neuroinflammation. Because enhanced leukocyte migration across the BBB is a major feature of neuroinflammation, we tested whether PPAR{gamma} activation in cytokine stimulated human BMVEC could control monocyte adhesion and migration. We found that PPAR{gamma} activation in BMVEC resulted in significant reduction of monocyte adhesion and migration in our BBB culture model. Analysis of the Rho family GTPases in cytokine stimulated and TZD treated BMVEC resulted in dose dependent inhibition of Rac1 and RhoA that paralleled diminished monocyte adhesion and migration across BMVEC monolayers. Also, we showed that TZD activation of PPAR{gamma} in stimulated BMVEC resulted in a significant decrease in the adhesion and transmigration of HIV-1 infected monocytes across brain endothelium. Together these observations provide a novel inhibitory mechanism on monocyte adhesion/migration by PPAR{gamma} ligands acting in endothelial cells forming the BBB.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Human BMVEC, monocytes, and viral infection

Primary human BMVEC were isolated from tissue derived from surgical removal of epileptogenic cerebral cortex, as described previously (20) and provided by Drs. Marlys Witte and Michael Bernas (University of Arizona, Tucson, AZ). The procedures were approved by the University of Nebraska Medical Center Institutional Review Board. BMVEC were maintained in DMEM/F-12 media containing 10% horse serum, endothelial cell growth supplement (BD Biosciences), heparin (100 mg/ml; Sigma-Aldrich), amphotericin B (2.5 µg/ml; Invitrogen Life Technologies), and gentamicin (50 µg/ml, Invitrogen Life Technologies). For all experiments only BMVEC cultures of low passage (passage 2–5) were used. For barrier formation, the cells were plated confluent in a given culture vessel and maintained in media containing the above components but lacking the endothelial cell growth supplement, which allows BMVEC to display typical morphological and functional barrier characteristics after 3–5 days in culture. BMVEC cultures were routinely evaluated for expression of endothelial cell markers (von Willebrand factor, CD31/PECAM-1, and TJ proteins (ZO-1, occludin, claudin-5)), and the lack of macrophage (CD68 and CD163), astrocyte (glial fribrillary acidic protein) and pericyte ({alpha}-myosin) markers. Barrier formation by BMVEC was confirmed by measurement of transendothelial electrical resistance, TEER.

Primary human peripheral blood monocytes were obtained from HIV-1 and hepatitis B seronegative donors by leukopheresis and were purified by countercurrent centrifugal elutriation (21). The monocytes were maintained in DMEM media with 10% heat inactivated pooled human serum, penicillin (100 U/ml), streptomycin (100 U/ml), and L-glutamine (2 mM) and used within 24 h of isolation. Monocytes were infected with HIV-1ADA at a multiplicity of infection of 0.01–0.1 virus/target cell for 4 h (21). Before infection, the HIV-1 cell-free stocks were treated with DNase I for 30 min at 37°C as described (22). All reagents were prescreened for endotoxin (<10 pg/ml; Associates of Cape Cod) and mycoplasma contamination (Gen-probe II; Gen-probe).

Microvessels isolation

Brain tissues (cortex) from patients without neuro-cognitive impairment or neuropathologic changes were obtained from the National NeuroAIDS Tissue Consortium and our Center for Neurovirology and Neurodegenerative Diseases brain bank. The clinical histories of brain tissue donors were described in Ref. 19 . The isolation procedure of microvessels was performed as described in Ref. 23 . Protein was extracted from each sample for Western blot. For immunofluorescent microscopy, 50 µl of microvessel suspension was spread on poly-l-lysine- or fibronectin-coated glass coverslips, air-dried, fixed for 20 min with a 4% paraformaldehyde (pH 7.4), rinsed with PBS, air-dried, and used for immufluorescent staining with Abs to tight junction protein, claudin-5, von Willebrand Factor; CD163 (macrophage marker) was used to confirm the vascular identity of the isolated microvessels as described (24).

Monocyte adhesion assay

BMVEC were plated on 96-well plates coated with rat-tail collagen type I (BD Biosciences) at a density of 2.5 x 104 cells/well. After formation of confluent monolayers, BMVEC were treated with PPAR{gamma} agonists or antagonists for 30 min before simultaneous incubation with recombinant human TNF-{alpha} (20 ng/ml; R&D Systems) for 4 h before the assay. The endothelial cells were rinsed of all treatments and fluorescently labeled monocytes (2.5 x 105 cells/well loaded with calcein-AM (Invitrogen Life Technologies) at 5 µM/1 x 106 cells for 45 min) were added to the endothelial monolayers and cocultured for 15 min at 37°C. After adhesion, the monolayers were washed three times with PBS and relative fluorescence was acquired on a fluorescence plate reader, Spectramax M5 (Molecular Devices). The data were calculated based on the standard curve derived from fluorescent intensity of known amounts of labeled monocytes. Results are represented as the fold difference, which is the number of monocytes that attached to endothelial cells with experimental condition over the number of monocytes that attached to endothelial cells without cytokine stimulation or drug treatment.

Transendothelial migration assay

The transendothelial migration assay was a fluorescence-based assay. In brief, BMVEC were plated on rat-tail collagen type I coated FluoroBlok tinted tissue culture inserts (with 3-µm pores; BD Biosciences) at a density of 2.5 x 104 cells/insert. Because monolayers were not visible on these inserts, manual readings of TEER were taken with a voltmeter (EVOM; World Precision Instruments) to confirm monolayer formation as described (19). Thereafter, endothelial cells were treated with PPAR acting compounds for 30 min and then coincubated for an additional 4 h with TNF-{alpha} (20 ng/ml). The inserts were washed of all treatments, and relevant β-chemokine, recombinant human monocyte chemotactive protein (MCP) –1 (CCL2/MCP-1, 30 ng/ml; R&D Systems) was introduced into the lower chamber to create a chemokine gradient present in neuroinflammatory disorders (5, 25). Labeled monocytes (2.5 x 105 cells/insert loaded with calcein-AM at 5 µM/1 x 106 cells for 45 min) were placed on the upper chamber, and migration was allowed to continue up to 2 h at 37°C. Migration was monitored by taking the relative fluorescence with a fluorescence plate reader (Molecular Devices) of the labeled monocytes found in the lower chamber. The number of migrated monocytes was then derived by plotting against standard curves of the relative fluorescence from known numbers of monocytes. The data are presented as the fold difference, which is the number of migrating monocytes from the indicated experimental condition over the monocytes that migrated across untreated (no drug and no cytokine) endothelial cells without the presence of chemoattractant (left y-axis). Additionally, the data are shown as percent of input (right y-axis), which indicates the percent of cells that migrated from the number of cells inputted.

Endothelial cell transfection

Transfection of primary BMVEC was performed by nucleofection using the Nucleofector device (Amaxa System) according to protocol suggested by manufacturer. In brief, for each transfection reaction, 5.0 x 105 trypsinized endothelial cells were resuspended in 100 µl of nucleofection reagent along with 1 µg of vector DNA. Each reaction was transferred to an electroporation cuvette and placed in the nucleofector device for electroporation. The electroporated cells were plated in the configuration necessary for migration assay, adhesion assay, or Western blot. BMVEC were transfected with DNA constructs containing coding sequences for the following proteins: wild type RhoA (WT), constitutively active RhoA (G14V), dominant negative RhoA (T19N), WT Rac1, constitutively active Rac1 (G12V), and dominant negative Rac1 (T17N). Constructs were obtained from the University of Missouri-Rolla cDNA Resource Center (www.cdna.org). Transfection efficiency with the Amaxa system typically reached ~80%, as determined by flow cytometry.

The endothelial cells were also transfected with small hairpin RNA (shRNA) expressing vectors directed to PPAR{gamma} (GenBank accession number NM_138711). A scrambled sequence control and an empty vector control were also transfected. The silencing oligonucleotides were composed of the following: bases 1–21 antisense, 22–32 loop sequence, and 33–54 sense sequence. PPAR{gamma} shRNA sequence 1 (shPPAR{gamma}-1): 5'-TATTTGAGGAGAG TTACTTGGTTGATATCCGCCAAGTAACTCTCCTCAAATA-3', PPAR shRNA sequence 2 (shPPAR{gamma}-2) 5'-TAATGTGGAGTAGAAATGCTGTTGATATCCGCAGCATTTCTACTCCACATTA-3', and PPAR{gamma} shRNA sequence 3 (shPPAR{gamma}-3) 5'-TGTTCCGTGACAATCTGTCTGTTGATATCCGCAGACAGATTGTCACGGAACA-3'. All oligonucleotides were cloned into pRNAT-H1.1/Adeno vectors (Invitrogen Life Technologies) and were provided by GenScript.

Affinity precipitation and Western blot

Precipitations of the active form of Rho (RhoA-GTP) were performed from endothelial cell lysates by affinity purification using the EZ-Detect Rho activation kit from Pierce. In brief, each lysate (400 µg of total protein) was incubated with GST-rhotekin-RBD protein (400 µg) and introduced to an immobilized glutathione disc resin and incubated for 1 h at 4°C with gentle agitation. After incubation, the resin was washed 3 times with 1x Mg2+ lysis buffer followed by centrifugation at 14,000 x g for 30 s. The discs were then resuspended in Laemmli sample buffer containing 2-ME and boiled for 5 min at 95°C. Relevant controls such as guanosine 5'-O-(3-thio) triphosphate (GTP{gamma}S, for positive) and guanine diphosphate (GDP, for negative) were performed with untreated lysates and affinity precipitated as above.

Assays for active Rac1 (Rac-GTP) or Cdc42 (Cdc42-GTP) from cell lysates were also performed by affinity purification using the Rac1 or Cdc42 activation assays from Cytoskeleton. In brief, 2 mg of total protein from endothelial cellular lysates were incubated with 20 µg of PAK-PBD (p21 binding domain of p21 activated kinase 1) conjugated beads for 1 h at 4°C. After incubation, the PAK-PBD beads, which bind specifically to the active form of Rac1 or Cdc42, were washed twice with 1x wash buffer (25 mM Tris (pH 7.5), 30 mM MgCl2, and 40 mM NaCl) by centrifugation at 5000 x g for 3 min at 4°C. The rinsed beads were then resuspended in 10 µl of Laemmli buffer and analyzed by Western blot using specific Abs to distinguish between Rac1 and Cdc42.

Total protein lysates (10 µg) or precipitated proteins (quantities indicated above) were resolved by SDS-PAGE on 12% gels (Pierce), then transferred to nitrocellulose membranes and incubated with Abs against RhoA (1/500, Pierce), Rac1 (1/250, Cytoskeleton), Cdc42 (1/250 Cytoskeleton), PPAR{gamma}, PPARβ{delta}, PPAR{alpha} (1/500, Abcam), and hemagglutinin epitope (1/1000, Covance). For detection of tight junction proteins, membranous and cytoplasmic extractions were performed from lysed BMVEC according to the manufacturer’s protocol included with the ProteoExtract subcellular proteome extraction kit (Calbiochem). Western blots were then performed using the following Abs: occludin (1/500, US Biological), claudin-5 (1/500, US Biological), and ZO-1 (1/500, US Biological). Bound Abs were detected with HRP-conjugated secondary Abs (1/5000, Pierce) and exposed to Supersignal West Pico chemiluminescent substrate (Pierce). Signal visualization was obtained using the gel documentation system, G:Box Chemi HR16 (Syngene).

ELISA-based PPAR DNA binding assay and GTPase activation assay

BMVEC cells were treated as outlined in the figure legends, and analysis of PPAR{gamma} and PPAR{alpha} DNA binding was performed as instructed by the manufacturer using the transcription factor ELISA kits for PPAR{alpha} and PPAR{gamma} from Panomics. For GTPase ELISAs, BMVEC were treated as shown in the Fig. 1 legend and quantitation of RhoA and Rac1 GTPase activation was assessed following the manufacturer’s recommendations using the G-LISA small G-protein activation assays from Cytoskeleton.


Figure 1
View larger version (37K):
[in this window]
[in a new window]

  		FIGURE 1. PPAR{gamma} agonist, rosiglitazone, inhibited monocyte adhesion and migration across human BMVEC in a dose-dependent manner. A, PPAR protein expression profile derived from lysates of primary cultured BMVEC and isolated human brain microvessels. Passage 2 BMVEC monolayers and microvessels were lysed and analyzed by Western blot using specific Abs for the three known PPAR isotypes, PPAR{alpha} (top panel), PPARβ/{delta} (middle panel), and PPAR{gamma} (lower panel). B and C, BMVEC were treated with the indicated PPAR agonist (fibrate or TZD) in increasing concentrations; after 4 h, nuclear extractions were collected and introduced to oligo binding ELISA for PPAR{alpha} and PPAR{gamma} as described in the Materials and Methods. The values represent the mean ± SEM. D, Adhesion assays of BMVEC monolayers pretreated for 30 min with increasing concentrations of rosiglitatozone, pioglitazone, and fenofibrate with or without subsequent coincubation with TNF-{alpha} (20 ng/ml) for additional 4 h. All treatments were removed and calcein-AM labeled monocytes were introduced to the BMVEC, as described in the Materials and Methods. Monocytes were allowed to adhere for 15 min to the BMVEC, unattached cells were rinsed, and the fluorescence was measured. The data are represented as mean ± SEM fold difference, which is the adhesion value from treated BMVEC over the basal adhesion value from untreated cells. Where indicated, the addition of PPAR{gamma} antagonist GW9662 (50 µM) was used as control. E, Transendothelial monocyte migration across pretreated BMVEC monolayers toward CCL2/MCP-1 (30 ng/ml) was evaluated after 2 h as described in the Materials and Methods section. Data are represented as mean ± SEM fold difference (left y-axis) and percent of input (right y-axis) migration, which is the value from migration of treated cells over the "spontaneous" migration of untreated cells without chemoattractant. All data collected are from at least three independent experiments performed in triplicate. *, Statistically significant differences (p < 0.01) between untreated and rosiglitazone treated and cytokine stimulated BMVEC.

 
Flow cytometry

BMVEC were treated with TNF-{alpha} (20 ng/ml, 4 h) and/or rosiglitazone. Cells were lifted with 0.5 mM EDTA at 4°C, washed with flow cytometry buffer (eBioscience) then incubated with allophycocyanin-conjugated VCAM-1 Ab (BD Biosciences) or PE-conjugated ICAM-1 Ab (BD Biosciences) for 45 min at 4°C. Cells were washed, fixed with 2% paraformaldehyde, acquired on a FACSCalibur (BD Biosciences), and analyzed using CellQuest Pro software (BD Immunocytometry System).

ICAM-1 Ab crosslinking

ICAM-1 Ab crosslinking was conducted as previously described (26). In brief, BMVEC were seeded at 1.3 x 105 in six-well tissue culture plates and maintained under normal growth conditions for 5 days. Thereafter, the cells were incubated with TNF-{alpha} (20 ng/ml) for 4 h in the absence of growth factors but with serum, and then washed with 1x PBS. Treatment with PPAR{gamma} was performed for 30 min with or without TNF-{alpha} for 4 h as indicated. ICAM-1 crosslinking was conducted using mouse anti-human ICAM-1/CD54 Ab (R&D Systems) which was added to the endothelial cells for 10 min. Unbound Ab was removed by rinsing with PBS and then cells were incubated for 15 min with rabbit anti-mouse Abs (Santa Cruz Biotechnology). Cells were rinsed with PBS and then lysed for subsequent GTPase analysis (see above).

Transendothelial electrical resistance

TEER was measured in real time using the ECIS system model 1600R, (Applied Biophysics). Primary BMVEC were grown to confluence on collagen type I coated ECIS cultureware arrays (8W10E). Measurements were recorded with the following settings: current (1-volt), frequency (400Hz), at 5 min intervals. Treatments were performed as indicated in the figure legends and data were represented as normalized resistance, which is the resistance measured post treatment over the resistance acquired before treatment introduction (typically ~2600 {Omega}/cm2).

Statistical analysis

The experiments were independently performed multiple times (at least three times for all presented data) allowing statistical analyses. In each individual experiment, every condition was evaluated in three replicates. The data collected were analyzed using Prism v4.0 (GraphPad). The differences between the means were evaluated by Student’s t test, and statistical significance was considered at p values <0.01. All results were expressed as mean ± SEM.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
PPAR{gamma} agonist decreased monocyte adhesion and transendothelial migration

Because PPAR isotype distribution varies depending on the cell or tissue type and because no prior isotype expression has been documented in human brain endothelial cells, we sought to identify the expression profile in isolated human brain microvessels as well as in primary cultures of human BMVEC. Additionally, given that it is possible for primary cells to change a particular gene expression profile due to passage and culturing conditions, it was important to rule out whether there was a difference in the PPAR isotype expression between culture cells and intact microvessels. To this end, Western blot analysis of lysates from isolated microvessels and primary cultures were probed for each of the known PPAR isotypes. Fig. 1A shows the expression of PPAR{alpha}, PPARβ{delta}, and PPAR{gamma} in both sets of lysates. As seen in the Fig. 1, all three isotypes were expressed in brain microvessels and were also maintained in BMVEC cultures. Next, we examined PPAR{alpha} and PPAR{gamma} activation by oligo binding ELISA using two PPAR{alpha} agonists (fibrates) and three PPAR{gamma} agonists (TZDs). As shown in Fig. 1B, PPAR{alpha} oligo binding increased in a dose dependent manner with both fenofibrate and clofibrate, with fenofibrate inducing better binding (EC50 = 5.6 µM) compared with clofibrate (EC50 = 16.5 µM). Analysis of PPAR{gamma} activation by TZDs, rosiglitazone, pioglitazone, and ciglitazone resulted in rosiglitazone as a better activator (Rosi EC50 = 2.0 µM, Pio EC50 = 2.6 µM and Cig EC50 = 2.3 µM; Fig. 1C). Therefore, we used fenofibrate for PPAR{alpha} activation and rosiglitazone for PPAR{gamma} activation in subsequent analyses.

Because monocyte adhesion to brain endothelial cells is the initial step in migration across the BBB during neuroinflamation, and both PPAR{alpha} and PPAR{gamma} can inhibit inflammatory responses in the vasculature, we treated BMVEC with PPAR{alpha} and PPAR{gamma} ligands and tested monocyte adhesion. First, BMVEC were treated with PPAR agonist for 30 min and then coincubated with TNF-{alpha} (20 ng/ml) for 4 h. Treatments were removed and adhesion assay was performed as indicated in the Materials and Methods. Monocyte adhesion increased 15-fold when endothelial cells were stimulated with cytokine as shown in Fig. 1D. Pretreatment of BMVEC with various concentrations of PPAR{gamma} agonist led to a dose-dependent decrease in monocyte adhesion in both unstimulated and stimulated endothelial cells (Fig. 1D). At maximum, the reduction in monocyte adhesion seen in TNF-{alpha} activated BMVEC after treatment with rosiglitazone resulted in an 8-fold decrease in adhesion (p < 0.001) as compared with control. In addition to rosiglitazone, pioglitazone also produced a decrease in monocyte adhesion, resulting in a 4-fold decrease at the highest concentration tested. Surprisingly, no effect on monocyte adhesion was seen with the PPAR{alpha} agonist, fenofibrate. This observation is in contrast to previous analysis reporting that PPAR{alpha} activation could decrease the attachment of monocytes to endothelial cells (27). However, these experiments were performed in non-brain-derived endothelial cells. Thus, our data demonstrate that in brain endothelial cells, PPAR{gamma} activation can decrease monocyte adhesion but not when PPAR{alpha} is stimulated.

Next, we studied monocyte migration to determine whether PPAR{gamma} stimulation in BMVEC also could have an effect on monocyte transendothelial migration. In these experiments, we used CCL2/MCP-1 as a relevant chemokine produced during neuroinflammatory conditions, such as HIV-1 encephalitis (25). Fig. 1E shows the results of monocyte migrations across BMVEC monolayers; the results are represented as normalized fold values to monocytes migrating across BMVEC without the presence of CCL2/MCP-1. Basal migration across resting endothelial cells without chemoattractact is indicated as 1-fold (~6.5% from input), stimulation of endothelial cells with TNF-{alpha} and without CCL2/MCP-1 results in 1.3-fold increase (~8.5% from input), endothelial cells with CCL-2/MCP-1 in lower chamber gives a 2-fold (~12.6% from input) increase in migration, and BMVEC TNF-{alpha} stimulation with addition of CCL2/MCP-1 results in 4.3-fold (~25.5% from input) increase monocyte migration. Pretreatment of BMVEC with increasing concentrations of rosiglitazone (two shown) in the above treatment conditions produced significant decreases in transendothelial migration. Particularly when CCL2 and TNF-{alpha} were present, rosiglitazone produced a 21% decrease for 5 µM concentration and 35% at 50 µM concentration (p < 0.01). Similar inhibitory results on migration were also obtained with other PPAR{gamma} agonist, albeit at higher concentration (data not shown). Also shown in Fig. 1E, no significant change in migration of monocytes was observed with the PPAR{alpha} agonist, fenofibrate.

Knockdown expression by PPAR{gamma} specific shRNA abolished the effect of rosiglitazone on monocyte adhesion

To eliminate the possibility that the effects of rosiglitazone were not mediated through other cellular targets (28) or other PPAR family members, BMVEC were transfected with several PPAR{gamma}-specific shRNA. Three different shRNA sequences were evaluated for knocking down endogenous PPAR{gamma}. As shown in Fig. 2A, transfected shPPAR{gamma}-2 lowered endogenous PPAR{gamma} by 85%, as compared with ~60% for both shPPAR{gamma}-1 and shPPAR{gamma}-3. Because transfection with shPPAR{gamma}-2 showed the most prominent effect on PPAR{gamma} protein reduction, a control scramble sequence (shPPAR{gamma}-2-SC) of shPPAR{gamma}-2 was generated and transfected, which resulted in no observable PPAR{gamma} knock down (Fig. 2A). Next, we performed adhesion assays using transfected shPPAR{gamma}-2 and shPPAR{gamma}-2-SC in BMVEC, which had been treated with rosiglitazone and stimulated with TNF-{alpha} (Fig. 2B). The effect of rosiglitazone on monocyte adhesion was abolished in the shPPAR{gamma}-2 transfected BMVEC, but not in PPAR{gamma}-2-SC endothelial cells. These results indicated that endogenous PPAR{gamma} was indeed the primary target for the effect of rosiglitazone on monocyte adhesion because shRNA-mediated knockdown of PPAR{gamma} brought monocyte adhesion to control levels in the presence of the drug. The PPAR{gamma}-dependent mechanism was also observed in migration assays, where PPAR{gamma} knockdown resulted in the elimination of most of the migratory inhibition rendered by rosiglitazone (Fig. 2C). To ensure that the effects exerted by PPAR{gamma} knock-down were not the result of compromised barrier functionality, separate experiments showed that no difference in "tightness" of the barrier was observed as evaluated by TEER (data not shown).


Figure 2
View larger version (31K):
[in this window]
[in a new window]

  		FIGURE 2. shRNA-mediated PPAR{gamma} knockdown in BMVEC eliminates the effects of rosiglitazone on monocyte adhesion and migration. A, Western blot analysis showing knockdown of endogenous PPAR{gamma} expression in BMVEC (72 h post transfection) with vectors coding shRNA sequences directed to PPAR{gamma}. Three candidate sequences were evaluated denoted as shPPAR{gamma}-1, shPPAR{gamma}-2, and shPPAR{gamma}-3. The vector with shPPAR{gamma}-2-SC, lane 5, Represents the scrambled control for shPPAR{gamma}-2 (lane 3). B, Adhesion assays of BMVEC expressing shPPAR{gamma}-2, control scramble shPPAR{gamma}-2-SC, and mock transfected (NT). After 5 days posttransfection, the cells were treated with increasing concentration of rosiglitazone, and adhesion assays were performed. C, Migration assays of transfected BMVEC with the knockdown sequence and control. After 5 days, cells were pretreated with rosiglitazone along with or without cytokine stimulation for 4 h; migration was then performed for 2 h and values collected. The data for the adhesion and migration is represented as mean ± SEM fold difference and percent of input (migration only).

 
PPAR{gamma} activation did not affect the expression of adhesion molecules in cytokine-stimulated BMVEC

PPAR{gamma} ligands have been shown to suppress the transcriptional activity of factors mediating the up-regulation of adhesion molecules (i.e., NF-{kappa}B and STATs). Thus, we investigated whether this mechanism could be responsible for the observed inhibition on monocyte adhesion. Both ICAM-1/CD54 and VCAM-1/CD106 are critical for firm monocyte attachment to the endothelium. Representative histograms of BMVEC surface expression of ICAM-1 and VCAM-1 by flow cytometry are shown in Fig. 3A. Unexpectedly, the up-regulation in surface expression of both ICAM-1 and VCAM-1 seen after 4 h stimulation with TNF-{alpha} was not decreased with prior pretreatment with 50 µM rosiglitazone. In addition, surface expression of ICAM-1 and VCAM-1 was also unchanged in resting cells. Of note, using natural PPAR ligands in human aortic endothelial cells, others have also shown the lack of regulation in adhesion molecule expression by PPAR{gamma} (29).


Figure 3
View larger version (25K):
[in this window]
[in a new window]

  		FIGURE 3. PPAR{gamma} activation did not alter ICAM-1 and VCAM-1 surface expression of stimulated BMVEC or induce changes to barrier properties. A, Flow cytometry of BMVEC ICAM-1/CD54 and VCAM-1/CD106 surface staining following addition of rosiglitazone (RS, 50 µM) for 30 min and simultaneous incubation with TNF-{alpha} (20 ng/ml) for 4 h. B, BMVEC grown to confluence on ECIS electrode chamber slides were used to analyze for differences in TEER. The measurements shown represent recordings acquired at 5 min intervals at the parameters described in the Materials and Methods. The single arrow designates the pretreatment with 50 µM of rosiglitazone following coincubation with TNF-{alpha} as shown by the double arrow. Addition of lindsidomide at 100 µM was used as a control for lowering TEER. The data are presented as normalized resistance, which is the resistance measured post treatment over the resistance acquired before treatment introduction (typically ~2600 {Omega}/cm2). C, Western blot analysis of TJ proteins ZO-1, occludin1, and claudin-5 from the cytosolic (Cyto) and membranous (Mem) fractions of lysed BMVEC are shown; treatments are indicated in the figure.

 
PPAR{gamma} activation did not affect endothelial barrier properties

The paracellular (between cells) migration of monocytes across the BBB has been shown to be dependent in the orchestrated events occurring in endothelial cells that lead to tight junction (TJ) disassembly and permit migration. Thus, it is possible that PPAR{gamma} could be increasing barrier tightness via the TJ and therefore, limiting monocyte migration. To test this possibility, we analyzed changes in the TEER, and also on the expression and localization of TJ proteins after PPAR{gamma} treatment. Endothelial monolayers were cultured on coated electrode chamber arrays and incubated with the indicated compounds, and in some cases coincubated with TNF-{alpha}. As Fig. 3B shows, the TEER measurements of treated BMVEC taken in real time for 6 h did not produce fluctuations in TEER of either rosiglitazone alone or when present with TNF-{alpha}. Also shown in Fig. 3B, the immediate and sustained drop in TEER measurement was produced by the NO donor, linsidomine, used as control for inducing barrier leakiness. Of note, application of TNF-{alpha} at 20 ng/ml concentrations, which was the concentration used in the functional assays reported here, resulted in only a slight and a transient decrease in TEER.

To further confirm the results of the TEER analysis, the expression and localization of TJ proteins, ZO-1, occludin, and claudin-5 were investigated. Cytosolic and membranous fractions from treated BMVEC, as indicated in Fig. 3C, were collected and probed for the TJ proteins shown. As presented in Fig. 3C, we found no differences in the expression or intracellular distribution of any of the three TJ proteins. Thus, effects on monocyte migration cannot be explained by changes in TJ protein content or distribution in the BMVEC after PPAR{gamma} activation.

PPAR{gamma} stimulation inhibited RhoA and Rac1 GTPases

Central to monocyte-endothelial interactions is the modulation of cytoskeletal components and surface adhesion molecules by the Rho family of small GTPases (16, 30). During neuroinflammation, brain endothelial cells up-regulate adhesion molecules such as ICAM-1 and VCAM-1 leading to increased leukocyte-endothelial recruitment and trafficking (31). Proinflammatory cytokines including TNF-{alpha}, IL-1β, and IL-6 induce the activation of the GTPases in endothelial cells (32) leading to receptor clustering (Rac1), important for leukocyte adhesion and cytoskeletal and TJ rearrangement (RhoA), important in transendothelial migration (15, 19).

To evaluate whether PPAR{gamma} stimulation modulated the activation state of members of the Rho family of GTPases, we performed affinity purification of the active forms of RhoA, Rac1, and Cdc42 in TNF-{alpha} treated BMVEC. After treatment, cells were lysed and subjected to affinity purification-based pull-down of the GTP bound active forms of RhoA, Rac1, and Cdc42. The pull-down assays used the binding domain of the effector protein that targets the particular GTPase. In agreement with previous reports, TNF-{alpha} stimulation increased the level of both GTP-bound RhoA and Rac1 in BMVEC (Fig. 4, A and B). PPAR{gamma} agonist, rosiglitazone, significantly decreased binding of active RhoA and Rac1 in a dose-dependent manner (Fig. 4, A and B). It is interesting to note that PPAR{gamma} stimulation appeared to inhibit more effectively Rac1 (~60% at 5 µM) than RhoA (~20% at 5 µM). Although TNF-{alpha} induced Cdc42 activation/GTP binding, surprisingly rosiglitazone did not reduce Cdc42-GTP binding, suggesting that PPAR{gamma} could modulate the activation status of only certain GTPases. PPAR{gamma} stimulation of the GTPases did not change protein expression because total protein expression of GTPases was not affected. Thus, these results suggest that PPAR{gamma} via GTPase regulation could be the underlying mechanism preventing monocyte adhesion and migration across activated endothelium after PPAR{gamma} stimulation.


Figure 4
View larger version (29K):
[in this window]
[in a new window]

  		FIGURE 4. PPAR{gamma} regulates activation of RhoA and Rac1 GTPases. GTPases from whole cell extracts were affinity immunoprecipitated from BMVEC after the indicated treatments. The top panels show Western blots of the active GTP bound RhoA (A), Rac1 (B), and Cdc42 (C) following affinity precipitation (top panel). Together with the active form of the GTPase are immunoblots showing the total GTPase (lower panels) content of inactive plus the active form from whole cell lysates. The included densitometry analysis depicts the ratios from the normalized values of the active GTPases from all treatments and compared with the normalized value from untreated cells. D–G, ELISA-based GTPase activation assays of Rac1 (D) and RhoA (E) were performed after BMVEC crosslinking of ICAM-1 surface molecules with specific Abs. Monocyte mediated activation of Rac1 (F) and RhoA (G) was performed by using BMVEC lysates collected after monocyte adhesion, monocytes were removed as previously described (19 ). The data are presented as the average ± SEM of three independent experiments each performed in triplicate. Symbols in the graph represent statistical significance of (p < 0.01). *, Compares values from untreated cells and TNF-{alpha} treated; **, values from untreated cells compared with those from TNF-{alpha}, rosiglitazone and crosslinked with ICAM-1; #, values from TNF-{alpha} and monocytes with TNF-{alpha}, monocytes and rosiglitazone (5 µM); ##, values from TNF-{alpha} and monocytes with TNF-{alpha}, monocytes, and rosiglitazone (50 µM).

 
PPAR{gamma} prevents RhoA and Rac-1 activation after ICAM-1 crosslinking or monocyte engagement

Although GTPases are activated by proinflammatory cytokines, as seen in Fig. 4, A and B, additional GTPase activation occurs after leukocyte-endothelial engagement. Ab crosslinking of adhesion molecules was used to emulate this interaction (26) leading to cytoskeletal rearrangement needed for leukocyte docking and extravasation. With Ab crosslinking to ICAM-1, we proceeded to investigate whether PPAR{gamma} mediated inhibition of RhoA and Rac1 could also be seen if further GTPase activation was induced. Using quantitative GTPase ELISA for Rac-1 and RhoA, we not only observed the induction in GTPase activation after addition of TNF-{alpha} (20 ng/ml for 4 h), but also found the further activation of the two GTPases triggered by ICAM-1 Ab crosslinking (Fig. 4, D and E). BMVEC exposed to rosiglitazone along with TNF-{alpha} stimulation and ICAM-1 crosslinking showed inhibition of Rac1 and RhoA. Lastly, application of monocytes to BMVEC monolayers resulted in Rac1 and RhoA activation (as seen with Ab crosslinking) (Fig. 4, G and F); rosiglitazone blocked these changes.

It is important to note that rosiglitazone inhibition of Rac1 and RhoA in these analyses, like the pull-down assays (Fig. 4, A and B), also appeared to be more efficient for Rac1. These effects on Rac1 may explain rosiglitazone effects in BMVEC inhibition of monocyte adhesion, because maximal inhibition is seen with 5 µM rosiglitazone similarly to that observed with Rac1 inhibition (Fig. 4D). In contrast, RhoA inhibition by rosiglitazone in the endothelial cells appeared less sensitive (Fig. 4E) at low concentrations, possibly explaining the effect on monocyte migration where the maximal inhibitory effect is seen with 50 µM (Fig. 1E). Lastly, analysis of GTPase activity was observed to be similar to those with Ab crosslinking when actual monocytes were used (Fig. 4, F and G). Taken together, the analysis on the GTPases provides support for the notion that in BMVEC PPAR{gamma} negatively modulates Rac1 and RhoA, thus affecting monocyte adhesion and migration.

PPAR{gamma} inhibits Rac1 mediated monocyte adhesion to activated brain endothelium

To further elucidate whether PPAR{gamma} inhibitory action on Rac1 and RhoA could influence monocyte adhesion, we examined monocyte adhesion to BMVEC expressing RhoA and Rac1 mutants. BMVEC were transfected with low concentrations (as outlined in the Materials and Methods) of DNA constructs expressing wild type (WT), constitutively active (CA) and dominant negative (DN) forms of Rac1 and RhoA. Inserts panels in Fig. 5, A and B show the expression of the various mutants: the first row denotes the detection of the 3xHA peptide tag fused to the mutants, the second row indicates the GTPase expression (endogenous plus mutant), and the third row shows the internal control ({alpha}-actin). After transfection, the cells were allowed to form monolayers and then treated as indicated (Fig. 5, A and B). Higher concentrations of rosiglitazone were omitted because maximal inhibition on adhesion was reached at 5 µM concentrations (as shown on Fig. 1). As shown in Fig. 5A, the expression of Rac-CA resulted in a 4-fold increase in monocyte adhesion even in unstimulated BMVEC as compared with controls (transfected with Rac-WT). TNF-{alpha} stimulation alone in endothelial cells produced increased monocyte adhesion in Rac-WT as previously observed, and yet 20% higher in Rac-CA expressing cells. Rosiglitazone application led to a 23 and 35% decrease in monocyte adhesion for 2 µM and 5 µM, respectively, in Rac-WT; the Rac-CA transfectants completely counteracted the actions of rosiglitazone in activated BMVEC pointing to Rac1 as a critical mediator of monocyte adhesion in BMVEC. Interestingly, expression of Rac-DN led to a decrease in baseline adhesion to the cytokine-stimulated monolayers (~36% as compared with Rac-WT), similar to the inhibition seen in rosiglitazone treated cells at the maximal effective dose (5 µM, Fig. 5A).


Figure 5
View larger version (42K):
[in this window]
[in a new window]

  		FIGURE 5. Stimulation of PPAR{gamma} in activated BMVEC prevents Rac-1 mediated monocyte adhesion. BMVEC were transfected with expression vectors for wild type (WT), constitutively active (CA), and dominant negative (DN) Rac1 and RhoA. Five days post transfection, the cells were treated with two increasing concentrations of rosiglitazone (2 µM and 5 µM). Where indicated the cells were also pretreated with antagonist GW9662 as control. Figure inserts in A and B show the BMVEC expression of the mutant GTPase by Abs that detected the hemagglutin epitope (HA) fused to the expressing GTPase (top row), along with the proteins detected by RhoA or Rac1 Abs (middle row), and actin (bottom row). After transfection and treatments, the BMVEC were used in adhesion assays. The data are presented as the mean ± SEM adhesion fold difference of transfectants with the Rac1 (A) and RhoA (B) mutants. *, Statistical significance (p < 0.01) when compared with the value from stimulated adherent cells without PPAR{gamma} agonist.

 
In stark contrast to the functional analysis performed with the Rac1 mutants, the RhoA mutants had no effect on the response of rosiglitazone-treated endothelial cells, Fig. 5B. TNF-{alpha} stimulation of BMVEC led to ~10-fold increase in monocyte adhesion regardless of the RhoA mutant the endothelial cells were transfected with. The expression of Rho-CA and Rho-DN did not change the inhibitory effect of PPAR{gamma} agonist on monocyte adhesion as compared with control Rho-WT, suggesting that although TNF-{alpha} induced RhoA activation and PPAR{gamma} mediated its partial inhibition, PPAR{gamma} effects on RhoA did not contribute to monocyte adhesion to activated BMVEC. It is important to point out that all inhibitory effects on monocyte adhesion produced by rosiglitazone were reversed by coincubation with high affinity PPAR{gamma} antagonist ligand (GW9662), ensuring that over-expression of the mutants did not alter the specific action of the agonist (Fig. 5A).

RhoA-mediated monocyte migration across brain endothelium was attenuated in response to endothelial PPAR{gamma} activation

Previous studies identified the importance of RhoA in transendothelial migration (15). It was demonstrated that RhoA is a key mediator of TJ "gating", which promotes leukocyte trafficking across brain endothelial cells (19, 33). We performed experiments to determine whether mutant GTPase expression in endothelial cells could affect PPAR{gamma} inhibitory function of monocyte migration. Monocyte migration toward CCL2/MCP-1 was enhanced across TNF-{alpha}-activated BMVEC expressing Rho-CA (5.1-fold) and was significantly diminished by Rho-DN (1.8-fold) as compared with cells transfected with the Rho-WT (4.1-fold, p < 0.001, Fig. 6A). Although treatment with rosiglitazone diminished monocyte migration in BMVEC transfected with control Rho-WT in a dose-dependent fashion (21% with 5 µM or 35% with 50 µM), minimal inhibition (11%) was achieved in rosiglitazone-treated BMVEC expressing Rho-CA regardless of drug concentration. Similarly, no change in monocyte migration was found in BMVEC transfected with Rho-DN after PPAR{gamma} agonist treatment as compared with cells transfected with Rho-DN but without rosiglitazone application. Therefore, under these experimental conditions, transfection of cells with Rho-CA mostly counteracted the effects of PPAR{gamma} on monocyte migration, suggesting the role of PAPR{gamma} in regulating the role of RhoA in transendothelial migration.


Figure 6
View larger version (22K):
[in this window]
[in a new window]

  		FIGURE 6. Activation of PPAR{gamma} in BMVEC inhibits RhoA-mediated transendothelial migration of monocytes. BMVEC were transfected with GTPase mutants and allowed to express the transgene for 5 days followed by treatment with or without PPAR{gamma} agonist, rosiglitazone, at 5 µM and 50 µM with or without TNF-{alpha} coincubation. The figure shows CCL2/MCP-1 driven monocyte migration across BMVEC expressing RhoA (A) and Rac1 (B) mutants. The migration assay was conducted for 2 h and the relative fluorescence of labeled monocytes was measured. Asterisk indicates statistical significance (p < 0.01) when compared with the value from stimulated cells in the presence of CCL2/MCP-1 but without rosiglitazone. Data are represented as the migration fold difference (left y-axis) and percent of input (right y-axis) mean ± SEM from at least three independent experiments performed in triplicate.

 
We next analyzed the impact of rosiglitazone on monocyte migration in BMVEC transfected with Rac1 mutants. As expected, CCL2/MCP-1-driven monocyte migration was enhanced across TNF-{alpha} stimulated BMVEC expressing Rac-CA (15%) as compared with cells transfected with the Rac-WT (p < 0.01, Fig. 6B), while Rac-DN expression led to diminution of cell passage (23%). The range of these changes in migration was much less prominent as compared with results obtained with respective RhoA mutants. Monocyte migration across BMVEC expressing Rac-CA was reduced by rosiglitazone only at the higher concentration (50 µM), and the same trend existed for dominant negative Rac1. These data suggested that PPAR{gamma} effects on RhoA rather than Rac1-mediated changes of monocyte migration. Moreover, these results indicated that Rac1 inactivation occurred in a seemingly dose-sensitive manner, such that the effect of agonist at low concentration is more profound on Rac1 than for RhoA. These results underscored the dual modulation of PPAR{gamma} activation on RhoA and Rac1.

PPAR{gamma} stimulation in BMVEC monolayers inhibited adhesion and transendothelial migration of HIV-1 infected monocytes

To evaluate whether activators of PPAR{gamma} could protect the brain against infiltration of HIV-1 infected monocytes, we infected monocytes with HIV-1ADA, CCR5-tropic HIV-1 strain, for 4 h and then applied virus-infected monocytes to cytokine stimulated BMVEC pretreated with rosiglitazone. The infected monocytes were analyzed in adhesion and migration assays. As shown in Fig. 7A, basal adhesion of infected monocytes to untreated BMVEC was increased by 5.5-fold when compared with the uninfected monocyte control. Consequently, adhesion was even higher when BMVEC monolayers were TNF-{alpha} stimulated, 16.5-fold vs 11.8-fold for uninfected monocyte control. Rosiglitazone treatment (PPAR{gamma} activation) of BMVEC readily attenuated the adhesion of HIV-1 infected monocytes ranging from 16.5-fold in untreated to 12.5, 9.5, and 5.8 for rosiglitazone concentrations 1, 5, and 50 µM, respectively (p < 0.01). Therefore, these data suggest that PPAR{gamma} stimulation in BMVEC prevented adhesion to HIV-1-infected monocytes to unstimulated as well as stimulated brain endothelium. Next, we examined rosiglitazone effects on transendothelial migration of infected monocytes. As shown in Fig. 7B, migration of HIV-1-infected monocytes was significantly enhanced in response to CCL2/MCP-1 as compared with uninfected cells (p < 0.001). Furthermore, HIV-1-infected monocytes showed 1.7-fold enhanced migration across TNF-{alpha} activated endothelium as compared with uninfected cells. Addition of rosiglitazone to the cytokine-stimulated monolayers resulted in ~50% inhibition in the migration of infected or uninfected cells. These observations point to novel therapeutic approaches in using PPAR{gamma} agonists to prevent infiltration of HIV-1-infected monocytes across the BBB.


Figure 7
View larger version (14K):
[in this window]
[in a new window]

  		FIGURE 7. PPAR{gamma} activation in BMVEC inhibited adhesion and transendothelial migration of HIV-1 infected monocytes. Adhesion (A) and migration (B) assays using uninfected or HIV-1ADA (MOI 0.01) infected monocytes were performed. For adhesion assays, the endothelial cells were exposed to increasing concentrations of rosiglitazone, 1, 5, and 50 µM, and where indicated cells were also simultaneously incubated with TNF-{alpha} (20 ng/ml) for 4 h. Data are represented as adhesion fold differences as described earlier. For migration assays BMVEC monolayers were preincubated with rosiglitazone (50 µM) with or without TNF-{alpha} (20 ng/ml) following the same treatments times as before. Data are represented as dual y-axis for the migration fold difference (left) and percent of input (right) mean ± SEM. *, Statistical significance (p < 0.01) when compared with the value from migrated cells toward CCL2/MCP-1 but without cytokine stimulation. **, Statistical significance (p < 0.01) when compared with values from uninfected cells migrating toward CCL2/MCP-1 and monolayers treated with cytokine. #, Statistical significance (p < 0.01) of values from infected cells migrated toward CCL2/MCP-1 on monolayers treated with TNF-{alpha} and rosiglitazone compared with infected cells migrating toward CCL2/MCP-1 but without rosiglitazone treatment.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
The responses of the endothelium to neuroinflammatory conditions play a significant role in the regulation of immune cell infiltration into the brain parenchyma (34, 35). Whether CNS inflammation arises from an autoimmune (multiple sclerosis) or from a pathogen-driven disorder as in the case of HIV-1 encephalitis, immune cell migration has damaging effects to the BBB and to the neuronal environment (19, 36). Once immune cells cross the BBB, a cascade of events, in part orchestrated by astrocytes and other glia cells, contributes to potentiation of CNS inflammation. In this report, we explored the anti-inflammatory effects of PPAR ligands in preventing interactions between brain endothelium and monocytes. Using primary human BMVEC, we modeled the human BBB in vitro and simulated a condition of chronic inflammation (cytokine stimulated BMVEC) and then performed quantitative analysis of monocyte adhesion and transendothelial migration. Our analyses indicated that PPAR{gamma} activation by potent TZD, such as rosiglitazone led to a significant reduction in monocyte adhesion and migration in resting and stimulated BMVEC. This process was highly specific for PPAR{gamma}, as shown by knockdown of PPAR{gamma} in BMVEC and failure of selective PPAR{alpha} agonist to exhibit similar effects. In this study, we demonstrated the inhibition of Rac1 and RhoA GTPases by PPAR{gamma} stimulation in brain endothelium and provided evidence that this is the mechanism preventing monocyte engagement and passage across brain endothelium. Lastly, as proof of concept, we showed that synthetic PPAR{gamma} agonist hindered adhesion and migration of HIV-1 infected monocytes. Taken together, our data suggest that PPAR{gamma} activation in brain endothelium may be a strategy for counteracting CNS inflammation contributed by immune cell infiltration.

It is recognized that PPARs agonists could be useful in attenuating inflammatory responses (13, 37). PPARs are nuclear hormone receptors, which are ligand activated and act as transcription factors. The three isotypes of PPARs (PPAR{alpha}, PPAR{gamma}, and PPARβ/{delta}) are expressed in endothelium and have been studied as agents to curb the inflammation in atherosclerosis (13). Although up to date, no studies have been performed to evaluate the anti-inflammatory effect of PPARs activation in human brain endothelial cells, a recent study demonstrated the inhibitory effect of PPAR{gamma} stimulation on CD4+ lymphocyte adhesion and migration across monolayers of mouse brain endothelial cells (38). As CNS inflammation is attributed in part to the infiltration of immune cells across brain endothelium, we first evaluated whether activation of PPAR{alpha} and PPAR{gamma} could prevent monocyte adhesion to endothelial cells and transendothelial migration. Using PPAR{gamma} and PPAR{alpha} stimulators, we demonstrated that PPAR{gamma} stimulation and not PPAR{alpha} exerted a striking dose-dependent inhibition of monocyte adhesion and migration across activated BMVEC. This observation differs from those reported for aortic vascular endothelium where either PPAR{alpha} and PPAR{gamma} activation prevents monocyte adhesion (12, 39). Although rosiglitazone is a highly specific PPAR{gamma} agonist, it is possible that the observed effects occur via other intracellular factors independent of PPAR{gamma} as suggested by Chawla and colleagues (28). Using targeted shRNA down-regulation of endogenous PPAR{gamma}, we observed near complete reversal of monocyte adhesion/migration when the BMVEC were treated with rosiglitazone indicating specificity of PPAR{gamma} effects in BMVEC.

To address the underlying mechanism of diminished monocyte adhesion, we analyzed the expression of adhesion molecules ICAM-1 and VCAM-1 in TNF-{alpha} stimulated BMVEC. Although PPAR{gamma} stimulation was shown to down-regulate ICAM-1 and VCAM-1 in some experimental systems (38, 40), we did not find an appreciable effect on surface expression of adhesion molecules. Consistent with our data, others previously reported a lack of effect on ICAM-1 and VCAM-1 regulation after activation of PPAR{gamma} in TNF-{alpha}-stimulated human aortic endothelial cells using the natural ligands belonging to the conjugated linoleic acid class of fatty acids (29). It is possible that the effect on the expression of adhesion molecules by PPAR{gamma} could occur if treatment with PPAR{gamma} ligands was extended beyond the few hours performed in this study (38, 40). Similarly, the PPAR{gamma} agonist rosiglitazone did not change barrier function of BMVEC monolayers (measured by TEER) or distribution/level of TJ proteins in brain endothelium.

We next considered the possibility that PPAR{gamma} activation could inhibit the Rho family of GTPases, given that leukocyte adhesion and migration are tightly regulated by GTPase function in endothelial cells (15, 16). All Rho family members act as molecular switches by binding GDP, rendering inactivation, or GTP to shift into the activation state. GTP-bound GTPases act on effectors that then induce changes to cytoskeletal dynamics and gene regulation (41). In the endothelium, RhoGTPases are activated in response to inflammatory stimuli (such as TNF-{alpha}, IL-1β, and bacterial toxins), hypoxia, shear stress (33, 42, 43, 44, 45, 46), or endothelial-leukocyte interactions (19, 31). RhoA and Rac1 were activated in BMVEC after TNF-{alpha} treatment and further enhanced by monocyte-BMVEC engagement or simulation of this process by ICAM-1 Ab crosslinking. We found that PAPR{gamma} activation markedly decreased the level of active GTP-bound Rac1 and RhoA. The maximal inhibition of Rac1 occurred at low concentrations of PPAR{gamma} agonist, whereas most prominent RhoA inhibition was achieved at higher doses. Using BMVEC-expressing CA and DN mutants of Rac1 and RhoA, we showed that PPAR{gamma} inhibition of Rac1 impacted monocyte adhesion; whereas, RhoA suppression affected monocytes transendothelial migration. Expression of the Rac-CA mutant had an overriding effect on monocyte adhesion even when PPAR{gamma} was activated. Conversely, Rho-CA did not counteract the inhibitory effect of the PPAR{gamma} agonist on monocyte adhesion. In the case of migration, the Rho-CA mutant showed significant increase in monocyte migration with a minimal inhibitory effect achieved by PPAR{gamma} activation. The Rac-CA mutant was able to supersede PPAR{gamma}-induced inhibition on monocyte migration only at the lower and not at the higher concentrations of rosiglitazone, while the Rho-CA showed an equipotent response to all doses. Taken together these results suggest a dose-dependent inhibition on Rac1 and RhoA GTPase activity. To our knowledge, this is the first time that PPAR{gamma} agonist are reported to negatively regulate both RhoA and Rac1 in brain endothelium or endothelial cells of any origin. The only available study on RhoA inhibition by PPAR{gamma} stimulation was performed in smooth muscle where PPAR{gamma} in aortic smooth muscle cells could induce the up-regulation of the protein tyrosine phosphatase SHP-2, leading to inhibition of the RhoA/Rho kinase pathway (14). Additional studies will be necessary to elucidate whether a similar mechanism is operational in the endothelium as wells as how PPAR{gamma} may regulate function of multiple GTPases and whether this mechanism occurs by transcription-dependent or independent mechanisms.

A number of neuroinflammatory disorders (such as multiple sclerosis or encephalitis) are associated with monocyte infiltration across BBB leading to neuronal injury and neurological demise (47). HIV-1 encephalitis is characterized by monocyte and macrophage accumulation in affected brain tissue (48). Perivascular macrophages serve as a source of neurotoxins and viral reservoir, and they are a driving force of chronic inflammation providing chemokines and homing cues for circulating HIV-1 infected cells (49, 50). A pool of perivascular virus-infected macrophages is derived from monocytes migrating across the BBB and suppression of monocyte infiltration may ameliorate neuronal demise (50). PPAR{gamma} stimulation significantly diminished adhesion and migration of HIV-1 infected monocytes across BMVEC monolayers. The evidences provided in this study of PPAR{gamma}-mediated inhibition on Rac1 and RhoA GTPases extend our previous findings showing that RhoA activation is required in the BMVEC during interactions with HIV-1 infected monocytes, and its suppression prevents monocyte migration and BBB dysfunction (19). Taken together, these findings suggest a novel role for PPAR{gamma} at the BBB, which offers a therapeutic strategy to diminishing infiltration of leukocytes into the brain parenchyma.


   Acknowledgments
 
We thank Dr. Georgette Kanmonge for providing human microvessel lysates, Dr. Anuja Ghorpade for critical reading of this manuscript, and Robin Taylor and Debra Baer for excellent editorial support.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by Grants AA015913 and MH65151 from the National Institutes of Health (to Y.P.). Back

2 Address correspondence and reprint requests to Dr. Yuri Persidsky, Departments of Pathology/Microbiology and Pharmacology/Experimental Neuroscience, 985215 Nebraska Medical Center, Omaha, NE 68198. E-mail address: ypersids{at}unmc.edu Back

3 Abbreviations used in this paper: BBB, blood brain barrier; BMVEC, human brain microvascular endothelial cells; PPAR, peroxisome proliferator-activated receptors; TEER, transendothelial electrical resistance; TZD, thiazolidinediones; shRNA, small hairpin RNA; TJ, tight junction; WT, wild type; CA, constitutively active; DN, dominant negative. Back

Received for publication July 26, 2007. Accepted for publication November 19, 2007.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Engelhardt, B., R. M. Ransohoff. 2005. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 26: 485-495. [Medline]
  2. Kanwar, J. R.. 2005. Anti-inflammatory immunotherapy for multiple sclerosis/experimental autoimmune encephalomyelitis (EAE) disease. Curr. Med. Chem. 12: 2947-2962. [Medline]
  3. Persidsky, Y., H. E. Gendelman. 2003. Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection. J. Leukocyte Biol. 74: 691-701. [Abstract/Free Full Text]
  4. Stalder, A. K., F. Ermini, L. Bondolfi, W. Krenger, G. J. Burbach, T. Deller, J. Coomaraswamy, M. Staufenbiel, R. Landmann, M. Jucker. 2005. Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. J. Neurosci. 25: 11125-11132. [Abstract/Free Full Text]
  5. Eugenin, E. A., K. Osiecki, L. Lopez, H. Goldstein, T. M. Calderon, J. W. Berman. 2006. CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and NeuroAIDS. J. Neurosci. 26: 1098-1106. [Abstract/Free Full Text]
  6. Dietrich, J. B.. 2002. The adhesion molecule ICAM-1 and its regulation in relation with the blood-brain barrier. J. Neuroimmunol. 128: 58-68. [Medline]
  7. Quandt, J., K. Dorovini-Zis. 2004. The β chemokines CCL4 and CCL5 enhance adhesion of specific CD4+ T cell subsets to human brain endothelial cells. J. Neuropathol. Exp. Neurol. 63: 350-362. [Medline]
  8. Desvergne, B., W. Wahli. 1999. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20: 649-688. [Abstract/Free Full Text]
  9. Lehrke, M., M. A. Lazar. 2005. The many faces of PPAR{gamma}. Cell 123: 993-999. [Medline]
  10. Zingarelli, B., J. A. Cook. 2005. Peroxisome proliferator-activated receptor-{gamma} is a new therapeutic target in sepsis and inflammation. Shock 23: 393-399. [Medline]
  11. Brown, J. D., J. Plutzky. 2007. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 115: 518-533. [Abstract/Free Full Text]
  12. Kurebayashi, S., X. Xu, S. Ishii, M. Shiraishi, H. Kouhara, S. Kasayama. 2005. A novel thiazolidinedione MCC-555 down-regulates tumor necrosis factor-{alpha}-induced expression of vascular cell adhesion molecule-1 in vascular endothelial cells. Atherosclerosis 182: 71-77. [Medline]
  13. Zandbergen, F., J. Plutzky. 2007. PPAR{alpha} in atherosclerosis and inflammation. Biochim. Biophys. Acta 1771: 972-982. [Medline]
  14. Wakino, S., K. Hayashi, T. Kanda, S. Tatematsu, K. Homma, K. Yoshioka, I. Takamatsu, T. Saruta. 2004. Peroxisome proliferator-activated receptor {gamma} ligands inhibit {rho}{rho} kinase pathway by inducing protein tyrosine phosphatase SHP-2. Circ. Res. 95: e45-e55. [Abstract/Free Full Text]
  15. Wittchen, E. S., J. D. van Buul, K. Burridge, R. A. Worthylake. 2005. Trading spaces: Rap, Rac, and {rho} as architects of transendothelial migration. Curr. Opin. Hematol. 12: 14-21. [Medline]
  16. Cernuda-Morollon, E., A. J. Ridley. 2006. {rho} GTPases and leukocyte adhesion receptor expression and function in endothelial cells. Circ. Res. 98: 757-767. [Abstract/Free Full Text]
  17. Greenwood, J., C. L. Amos, C. E. Walters, P. O. Couraud, R. Lyck, B. Engelhardt, P. Adamson. 2003. Intracellular domain of brain endothelial intercellular adhesion molecule-1 is essential for T lymphocyte-mediated signaling and migration. J. Immunol. 171: 2099-2108. [Abstract/Free Full Text]
  18. Muro, S., R. Wiewrodt, A. Thomas, L. Koniaris, S. M. Albelda, V. R. Muzykantov, M. Koval. 2003. A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J. Cell Sci. 116: 1599-1609. [Abstract/Free Full Text]
  19. Persidsky, Y., D. Heilman, J. Haorah, M. Zelivyanskaya, R. Persidsky, G. A. Weber, H. Shimokawa, K. Kaibuchi, T. Ikezu. 2006. {rho}-mediated regulation of tight junctions during monocyte migration across the blood-brain barrier in HIV-1 encephalitis (HIVE). Blood 107: 4770-4780. [Abstract/Free Full Text]
  20. Persidsky, Y., M. Stins, D. Way, M. H. Witte, M. Weinand, K. S. Kim, P. Bock, H. E. Gendelman, M. Fiala. 1997. A model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis. J. Immunol. 158: 3499-3510. [Abstract]
  21. Gendelman, H. E., J. M. Orenstein, M. A. Martin, C. Ferrua, R. Mitra, T. Phipps, L. A. Wahl, H. C. Lane, A. S. Fauci, D. S. Burke, et al 1988. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J. Exp. Med. 167: 1428-1441. [Abstract/Free Full Text]
  22. Ghorpade, A., A. Nukuna, M. Che, S. Haggerty, Y. Persidsky, E. Carter, L. Carhart, L. Shafer, H. E. Gendelman. 1998. Human immunodeficiency virus neurotropism: an analysis of viral replication and cytopathicity for divergent strains in monocytes and microglia. J. Virol. 72: 3340-3350. [Abstract/Free Full Text]
  23. Brooks, T. A., B. T. Hawkins, J. D. Huber, R. D. Egleton, T. P. Davis. 2005. Chronic inflammatory pain leads to increased blood-brain barrier permeability and tight junction protein alterations. Am. J. Physiol. 289: H738-H743.
  24. Nag, S.. 2003. Morphology and molecular properties of cellular components of normal cerebral vessels. Methods Mol. Med. 89: 3-36. [Medline]
  25. Persidsky, Y., A. Ghorpade, J. Rasmussen, J. Limoges, X. J. Liu, M. Stins, M. Fiala, D. Way, K. S. Kim, M. H. Witte, et al 1999. Microglial and astrocyte chemokines regulate monocyte migration through the blood-brain barrier in human immunodeficiency virus-1 encephalitis. Am. J. Pathol. 155: 1599-1611. [Abstract/Free Full Text]
  26. Etienne-Manneville, S., J. B. Manneville, P. Adamson, B. Wilbourn, J. Greenwood, P. O. Couraud. 2000. ICAM-1-coupled cytoskeletal rearrangements and transendothelial lymphocyte migration involve intracellular calcium signaling in brain endothelial cell lines. J. Immunol. 165: 3375-3383. [Abstract/Free Full Text]
  27. Rival, Y., N. Beneteau, T. Taillandier, M. Pezet, E. Dupont-Passelaigue, J. F. Patoiseau, D. Junquero, F. C. Colpaert, A. Delhon. 2002. PPAR{alpha} and PPAR{delta} activators inhibit cytokine-induced nuclear translocation of NF-{kappa}B and expression of VCAM-1 in EAhy926 endothelial cells. Eur. J. Pharmacol. 435: 143-151. [Medline]
  28. Chawla, A., Y. Barak, L. Nagy, D. Liao, P. Tontonoz, R. M. Evans. 2001. PPAR-{gamma} dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 7: 48-52. [Medline]
  29. Schleser, S., R. Ringseis, K. Eder. 2006. Conjugated linoleic acids have no effect on TNF {alpha}-induced adhesion molecule expression, U937 monocyte adhesion, and chemokine release in human aortic endothelial cells. Atherosclerosis 186: 337-344. [Medline]
  30. Wojciak-Stothard, B., L. Williams, A. J. Ridley. 1999. Monocyte adhesion and spreading on human endothelial cells is dependent on {rho}-regulated receptor clustering. J. Cell Biol. 145: 1293-1307. [Abstract/Free Full Text]
  31. Adamson, P., B. Wilbourn, S. Etienne-Manneville, V. Calder, E. Beraud, G. Milligan, P. O. Couraud, J. Greenwood. 2002. Lymphocyte trafficking through the blood-brain barrier is dependent on endothelial cell heterotrimeric G-protein signaling. FASEB J. 16: 1185-1194. [Abstract/Free Full Text]
  32. Nwariaku, F. E., P. Rothenbach, Z. Liu, X. Zhu, R. H. Turnage, L. S. Terada. 2003. {rho} inhibition decreases TNF-induced endothelial MAPK activation and monolayer permeability. J. Appl. Physiol. 95: 1889-1895. [Abstract/Free Full Text]
  33. Stamatovic, S. M., P. Shakui, R. F. Keep, B. B. Moore, S. L. Kunkel, N. Van Rooijen, A. V. Andjelkovic. 2005. Monocyte chemoattractant protein-1 regulation of blood-brain barrier permeability. J. Cereb. Blood Flow Metab. 25: 593-606. [Medline]
  34. Grigoriadis, N., S. Grigoriadis, E. Polyzoidou, I. Milonas, D. Karussis. 2006. Neuroinflammation in multiple sclerosis: evidence for autoimmune dysregulation, not simple autoimmune reaction. Clin. Neurol. Neurosurg. 108: 241-244. [Medline]
  35. Minghetti, L.. 2005. Role of inflammation in neurodegenerative diseases. Curr. Opin. Neurol. 18: 315-321. [Medline]
  36. Abbott, N. J., L. Ronnback, E. Hansson. 2006. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 7: 41-53. [Medline]
  37. Li, J., N. Wang. 2007. Peroxisome proliferator-activated receptor-{gamma} in vascular biology. Cardiovasc. Hematol. Disord. Drug Targets 7: 109-117. [Medline]
  38. Klotz, L., L. Diehl, I. Dani, H. Neumann, N. von Oppen, A. Dolf, E. Endl, T. Klockgether, B. Engelhardt, P. Knolle. 2007. Brain endothelial PPAR{gamma} controls inflammation-induced CD4+ T cell adhesion and transmigration in vitro. J. Neuroimmunol. 190: 34-43. [Medline]
  39. Jackson, S. M., F. Parhami, X. P. Xi, J. A. Berliner, W. A. Hsueh, R. E. Law, L. L. Demer. 1999. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler. Thromb. Vasc. Biol. 19: 2094-2104. [Abstract/Free Full Text]
  40. Arnold, R., M. Neumann, W. Konig. 2007. Peroxisome proliferator-activated receptor-{gamma} agonists inhibit respiratory syncytial virus-induced expression of intercellular adhesion molecule-1 in human lung epithelial cells. Immunology 121: 71-81. [Medline]
  41. Wennerberg, K., C. J. Der. 2004. {rho}-family GTPases: it’s not only Rac and Rho (and I like it). J. Cell Sci. 117: 1301-1312. [Abstract/Free Full Text]
  42. Li, S., B. P. Chen, N. Azuma, Y. L. Hu, S. Z. Wu, B. E. Sumpio, J. Y. Shyy, S. Chien. 1999. Distinct roles for the small GTPases Cdc42 and {rho} in endothelial responses to shear stress. J. Clin. Invest. 103: 1141-1150. [Medline]
  43. Munro, P., E. Lemichez. 2005. Bacterial toxins activating Rho GTPases. Curr. Top. Microbiol. Immunol. 291: 177-190. [Medline]
  44. Wojciak-Stothard, B., A. Entwistle, R. Garg, A. J. Ridley. 1998. Regulation of TNF-{alpha}-induced reorganization of the actin cytoskeleton and cell-cell junctions by {rho}, Rac, and Cdc42 in human endothelial cells. J. Cell. Physiol. 176: 150-165. [Medline]
  45. Turner, N. A., D. J. O’Regan, S. G. Ball, K. E. Porter. 2005. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. FASEB J. 19: 804-806. [Abstract/Free Full Text]
  46. Stamatovic, S. M., R. F. Keep, S. L. Kunkel, A. V. Andjelkovic. 2003. Potential role of MCP-1 in endothelial cell tight junction "opening": signaling via {rho} and {rho} kinase. J. Cell Sci. 116: 4615-4628. [Abstract/Free Full Text]
  47. Hawkins, B. T., T. P. Davis. 2005. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev. 57: 173-185. [Abstract/Free Full Text]
  48. Glass, J., H. Fedor, S. Wesselingh, J. McArthur. 1995. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann. Neurol. 38: 755-762. [Medline]
  49. Williams, K. C., S. Corey, S. V. Westmoreland, D. Pauley, H. Knight, C. deBakker, X. Alvarez, A. A. Lackner. 2001. Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: implications for the neuropathogenesis of AIDS. J. Exp. Med. 193: 905-915. [Abstract/Free Full Text]
  50. Williams, K., S. Westmoreland, J. Greco, E. Ratai, M. Lentz, W. K. Kim, R. A. Fuller, J. P. Kim, P. Autissier, P. K. Sehgal, et al 2005. Magnetic resonance spectroscopy reveals that activated monocytes contribute to neuronal injury in SIV neuroAIDS. J. Clin. Invest. 115: 2534-2545. [Medline]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
H. Dou, C. B. Grotepas, J. M. McMillan, C. J. Destache, M. Chaubal, J. Werling, J. Kipp, B. Rabinow, and H. E. Gendelman
Macrophage Delivery of Nanoformulated Antiretroviral Drug to the Brain in a Murine Model of NeuroAIDS
J. Immunol., July 1, 2009; 183(1): 661 - 669.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
W. Huang, S. Y. Eum, I. E Andras, B. Hennig, and M. Toborek
PPAR{alpha} and PPAR{gamma} attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities
FASEB J, May 1, 2009; 23(5): 1596 - 1606.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Alcaide, G. Newton, S. Auerbach, S. Sehrawat, T. N. Mayadas, D. E. Golan, P. Yacono, P. Vincent, A. Kowalczyk, and F. W. Luscinskas
p120-Catenin regulates leukocyte transmigration through an effect on VE-cadherin phosphorylation
Blood, October 1, 2008; 112(7): 2770 - 2779.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
R. Potula and Y. Persidsky
Adding Fuel to the Fire: Methamphetamine Enhances HIV Infection
Am. J. Pathol., June 1, 2008; 172(6): 1467 - 1470.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ramirez, S. H.
Right arrow Articles by Persidsky, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ramirez, S. H.
Right arrow Articles by Persidsky, Y.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS